|Neoadjuvant PD-1 blockade in resectable lung cancer|
PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ...
New England Journal of Medicine 378 (21), 1976-1986, 2018
|Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non–small cell lung cancer|
B Shankar, J Zhang, AR Naqash, PM Forde, JL Feliciano, KA Marrone, ...
JAMA oncology 6 (12), 1952-1956, 2020
|Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis|
H Abu-Sbeih, FS Ali, AR Naqash, DH Owen, S Patel, GA Otterson, ...
Journal of clinical oncology 37 (30), 2738, 2019
|Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease|
H Abu-Sbeih, DM Faleck, B Ricciuti, RB Mendelsohn, AR Naqash, ...
Journal of Clinical Oncology 38 (6), 576, 2020
|The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor ImmunityMANAFEST Assay for Detecting …|
L Danilova, V Anagnostou, JX Caushi, JW Sidhom, H Guo, HY Chan, ...
Cancer immunology research 6 (8), 888-899, 2018
|Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers|
JX Caushi, J Zhang, Z Ji, A Vaghasia, B Zhang, EHC Hsiue, BJ Mog, ...
Nature 596 (7870), 126-132, 2021
|Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989–2012: a matched case–control study|
J Zhang, C Haines, AJM Watson, AR Hart, MJ Platt, DM Pardoll, ...
Gut 68 (11), 1971-1978, 2019
|Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung CancerT-cell Dynamics …|
J Zhang, Z Ji, JX Caushi, M El Asmar, V Anagnostou, TR Cottrell, ...
Clinical Cancer Research 26 (6), 1327-1337, 2020
|A multidisciplinary toxicity team for cancer Immunotherapy–Related adverse events|
J Naidoo, J Zhang, EJ Lipson, PM Forde, K Suresh, KF Moseley, S Mehta, ...
Journal of the National Comprehensive Cancer Network 17 (6), 712-720, 2019
|Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression≥ 50%|
JF Gainor, H Rizvi, EJ Aguilar, F Skoulidis, BY Yeap, J Naidoo, ...
Annals of Oncology 31 (3), 404-411, 2020
|Precision immuno-oncology: prospects of individualized immunotherapy for pancreatic cancer|
J Zhang, CL Wolfgang, L Zheng
Cancers 10 (2), 39, 2018
|Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses|
AG Dykema, B Zhang, BA Woldemeskel, CC Garliss, LS Cheung, ...
The Journal of clinical investigation 131 (10), 2021
|Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal TumorsMSS Colorectal Tumor Immune Microenvironment|
NJ Llosa, B Luber, AJ Tam, KN Smith, N Siegel, AH Awan, H Fan, T Oke, ...
Clinical Cancer Research 25 (17), 5250-5259, 2019
|Neoadjuvant nivolumab in resectable non-small cell lung cancer: extended follow-up and molecular markers of response.|
JE Reuss, KN Smith, V Anagnostou, J Zhang, M Zahurak, J Caushi, ...
Journal of Clinical Oncology 37 (15_suppl), 8524-8524, 2019
|Considerations for treatment duration in responders to immune checkpoint inhibitors|
TU Marron, AE Ryan, SM Reddy, S Kaczanowska, RH Younis, D Thakkar, ...
Journal for immunotherapy of cancer 9 (3), 2021
|Immune-related adverse events requiring hospitalization: spectrum of toxicity, treatment, and outcomes|
A Balaji, J Zhang, B Wills, KA Marrone, H Elmariah, M Yarchoan, ...
Journal of oncology practice 15 (9), e825-e834, 2019
|Oral antibiotic use and chronic disease: long-term health impact beyond antimicrobial resistance and Clostridioides difficile|
J Queen, J Zhang, CL Sears
Gut Microbes 11 (4), 1092-1103, 2020
|A novel bioabsorbable pericardial membrane substitute to reduce postoperative pericardial adhesions in a rabbit model|
Z Chen, J Zheng, J Zhang, S Li
Interactive cardiovascular and thoracic surgery 21 (5), 565-572, 2015
|A multidisciplinary toxicity team for cancer immunotherapy-related adverse events.|
J Naidoo, L Cappelli, EJ Lipson, PM Forde, WH Sharfman, J Zhang, ...
Journal of Clinical Oncology 36 (15_suppl), 6538-6538, 2018
|New development of biomarkers for gastrointestinal cancers: From neoplastic cells to tumor microenvironment|
J Zhang, S Quadri, CL Wolfgang, L Zheng
Biomedicines 6 (3), 87, 2018